ArticleInvestigative ophthalmology & visual science2026
Downregulation of Cyclin Kinase Inhibitors p16INK4a and p27 in Conjunctival Melanomas.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Loss of cyclin-dependent kinase inhibitors p16INK4a, p27, and p21 has been linked to melanoma progression. We evaluated their expression in conjunctival melanocytic proliferations and explored correlations among genomic, RNA, and protein levels of p16INK4a. Methods: Expression of p16INK4a, p27, and p21 was analyzed by immunohistochemistry in 51 conjunctival nevi, 38 conjunctival melanocytic intraepithelial neoplasia (C-MIN), and 49 conjunctival melanomas (CJMs). Whole-genome/exome sequencing and RNA sequencing were available for 14 and 11 CJMs, respectively. Three CJM cell lines were treated with a DNA methyltransferase inhibitor. Results: p16INK4a was expressed in 92% of nevi, 23.7% of C-MIN, and 42.3% of CJMs; p27 in 98%, 13.5%, and 26.5%, respectively; and p21 in 33.3%, 2.8%, and 28.6%, respectively. Downregulation of p16INK4A and p27 in CJMs versus nevi was significant. No CDKN2A mutations were identified. One CJM showed homozygous CDKN2A loss and two had heterozygous loss, all lacking p16INK4a expression. Among 11 cases with normal ploidy, p16 mRNA was detected in eight (72.3%), but protein in only four (36.4%), suggesting post-transcriptional and post-translational regulation. Treatment with 5-aza-2'-deoxycytidine upregulated p16INK4a and reduced proliferation in two CJM cell lines. Conclusions: p16INK4a and p27 are significantly downregulated in CJM and may help in the histopathological differential diagnosis between melanoma and conjunctival nevus. p16INK4a loss involves genomic, epigenetic, and post-translational mechanisms. Restoring p16 function may reduce CJM aggressiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.